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Abstract: Critical illness, acute renal failure and continuous renal replacement therapy (CRRT) are 
associated with changes in pharmacokinetics. Initial antibiotic dose should be based on published 
volume of distribution and generally be at least the standard dose, as volume of distribution is usually 
unchanged or increased. Subsequent doses should be based on total clearance. Total clearance varies 
with the CRRT clearance which mainly depends on effluent flow rate, sieving coefficient/saturation 
coefficient. As antibiotic clearance by healthy kidneys is usually higher than clearance by CRRT, except 
for colistin, subsequent doses should generally be lower than given to patients without renal 
dysfunction. In the future therapeutic drug monitoring, together with sophisticated pharmacokinetic 
models taking into account the pharmacokinetic variability, may enable more appropriate 
individualized dosing. 
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Section on dosing of colistin and daptomycin. This section would greatly benefit from a final sentence 
for each of the two mentioned drugs summarizing the authors' opinions on how to approprialely 
manage dosage in this setting. 
The following statements have been added: 
In view of the uncertainty regarding colistin pharmacokinetics combined uncertainty regarding the 
optimal  pharmacokinetic / pharmacodynamic target we do not recommend calculating a dose but 
suggest giving at least the recommended dose for patients with normal renal function (3 million units 8 
hourly) for patients receiving CRRT with effluent rates of 2.1– 3.4L/h. Other authors have suggested a 
more aggressive regime of a loading dose of 9 million units, followed by a maintenance dose of up to 4.5 
million units 8 hourly, without the risk of toxicity[27].  
 
In view of its kill and toxicity characteristics, daptomycin should be dosed using an extended interval 
dosing regime. Using  the information and formulae above,  the method detailed in our previous 
publication [1], a minimum  dose and dosing interval  can be calculated. For Staphylococcal aureus blood 
stream infection with MIC of 0.5 mg/L for a 70kg patient with anuria on CVVHD using a Polysulfone filter 
and with targeted total effluent of 35 ml/kg/hour, a loading dose of 800mg daptomycin with subsequent 
maintenance dosing interval of 34 hours should achieve a Cmax/MIC of 100 and minimise the risk of 
adverse effects. (Figure 1).  However it is important to appreciate this calculated dose may need to be 
reduced in order to comply with dose range approved by regulatory authorities. It is of interest to note 
that healthy individuals receiving daptomycin at doses up to 12mg/kg daily for 14 days did not develop 
electrocardiographic or electrophysiological evidence of muscle or nerve toxicity[33].  
 
A ref. supporting the statement about Cmax/MIC ratio of daptomycin against Staph is needed. 
This had been added 
 
Table 1 should be removed as it's not essential for the purposes of the review 
The table has been removed 
 
Table 2: the term hour must be always reported as "h" throughout the table. Use 
piperacillin/tazobactam instead of Tazocin. Add footnotes with the meaning of the abbreviations 
The table has been amended 
 
Conclusions should also decribe briefly the authors' opinion on future directions. 
The following statement has been added: 
Future directions should include the conduct of large scale studies of patients receiving CRRT with 
creation of  pharmacokinetic models which can be used to generate recommendations on dosing 
changes in response to the results of therapeutic drug monitoring. This should be accompanied by 
development of therapeutic drug monitoring  with a rapid turn-around time to allow prompt 
adjustment. 
 
Minor comments.  
The acronym MIC should be used throughout the text after that it has been exploded the first time 
Manuscript amended 
 
Section on Pharmacokinetic change due to renal failure. Use changes and not change in the subheading. 
Linezolid must be considered as a lipophilic drug and not as an hydrophilic one. 
Manuscript amended 
*Detailed Response to Reviewers
Section on Pharmacokinetic change due to variability of CRRT. Use changes and not change in the 
subheading.  
Manuscript amended 
 
 
Section on Prescription of initial dose and subsequnt dose. Consider modifying subheadin as Prescription 
of initial loading dose and subsequent maintenance doses 
Manuscript amended 
 
There are some typo errors throughout the text. Please check carefully (i.e. doses and not dose in the 
highlights; demonstrates and not demonstrate, antibiotics and not antiotics in Ref. #21; 
pharmacokinetics and not pharmakinetics, pharmacodynamics and not pharmacodynmics, in the 
criticalli ill and not in critically ill in Ref. #23; demonstrates and not demonstrate, individualized and not 
individualised in Ref. #32)) 
Typos corrected 
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 Abstract 
Critical illness, acute renal failure and continuous renal replacement therapy (CRRT) are associated with 
changes in pharmacokinetics. Initial antibiotic dose should be based on published volume of distribution 
and generally be at least the standard dose, as volume of distribution is usually unchanged or increased. 
Subsequent doses should be based on total clearance. Total clearance varies with the CRRT clearance 
which mainly depends on effluent flow rate, sieving coefficient/saturation coefficient. As antibiotic 
clearance by healthy kidneys is usually higher than clearance by CRRT, except for colistin, subsequent 
doses should generally be lower than given to patients without renal dysfunction. In the future 
therapeutic drug monitoring, together with sophisticated pharmacokinetic models taking into account 
the pharmacokinetic variability, may enable more appropriate individualized dosing.  
Highlights 
 Pharmacokinetics vary markedly in critically ill patients receiving CRRT. 
 Prescribe initial doses of antibiotics based on volume of distribution 
 Prescribe subsequent doses based on CRRT and non CRRT clearance. 
 Unlike other antibiotics clearance of colistin by CRRT is greater than by healthy kidney. 
 Therapeutic drug monitoring is useful to further individualize drug dosing. 
 
Introduction 
Optimal dosing of antibiotics is difficult because doses cannot be titrated to effect. Instead dosing 
should be designed to achieve pharmacokinetic targets associated with optimal killing. The 
pharmacokinetic parameters vary with the class of antibiotic and the target values depend on the 
organism and the susceptibility of the organism, as reflected by the minimum inhibitory concentration 
(MIC) (table 1). Given that the targets are pharmacokinetic parameters, it is self-evident that 
appropriate antibiotic dosing in patients receiving continuous renal replacement therapies (CRRT) 
requires knowledge of the pharmacokinetic changes that occur in these patients as well as the 
clearances obtained by the specific CRRT used. 
Continuous renal replacement therapies are modes of therapy which are applied almost exclusively in 
Intensive Care Units. As a result drug pharmacokinetics in patients receiving CRRT are affected by 
changes due to critical illness, acute renal failure and the therapy. These issues have previously been 
reviewed by us [1] and will be dealt with only briefly here.  
 
Pharmacokinetic changes due to renal failure 
Changes in drug pharmacokinetics associated with critical illness and acute renal failure include 
increases in volume of distribution for some drugs (eg colistin [2], daptomycin [3,4], amikacin [5]) but 
not all. In general the volume of distribution of hydrophilic antibiotics (e.g. aminoglycosides, beta 
lactams, glycopeptides, linezolid) increases more than lipophilic antibiotics (e.g. macrolides, linezolid 
and fluoroquinolones) which already have a large volume of distribution [6]. Furthermore there may be 
increases in non-renal clearance [7] and some residual renal function despite the presence of acute 
renal failure and CRRT. 
There are three main modalities of continuous renal replacement therapy (CRRT): continuous veno-
venous haemodialysis (CVVHD), continuous veno-venous haemofiltration (CVVH) and continuous veno-
venous haemodiafiltration (CVVHDF). Clearance of solutes by these modalities is dependent on a 
number of factors as described in the following equations [1]: 
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Where ClCVVH (post)= clearance by continuous veno-venous haemofiltration with replacement fluid infused 
post-filter, ClCVVH (pre)= clearance by continuous veno-venous haemofiltration with replacement fluid 
infused pre-filter, ClCVVHD= clearance by continuous veno-venous haemodialysis, ClCVVHDF= clearance by 
continuous veno-venous haemodiafiltration, Qb=blood flow rate, Qd= dialysate flow rate, Qf= ultrafiltrate 
flow rate, Qrep=replacement fluid flow rate, Sc= sieving coefficient, Sd= saturation coefficient 
From these equations it can be seen that the main determinants of elimination by CRRT are sieving or 
saturation coefficient and effluent flow rate (ultrafiltration rate, dialysate flow rate or the two 
combined). Blood flow rate plays a relatively minor role. The sieving coefficient and the saturation 
coefficient describe the ratio of solute concentration in the blood to the solute concentration in 
ultrafiltrate (sieving coefficient) or the dialysate (saturation coefficient). Drugs are often bound to 
plasma proteins which are large molecules that cannot cross the dialysis or haemofiltration membrane 
and therefore only unbound drug (free drug) is dialyzed or filtered. As a result sieving coefficient and 
saturation coefficient are related to the unbound fraction. Acute phase changes in plasma protein 
concentrations are common in critical illness, affecting the sieving and saturation coefficients [8]. Thus, 
in critically ill patients these coefficients may not reflect the unbound fractions normally measured in 
healthy volunteers. Furthermore there may be significant patient to patient variation in these 
coefficients (table 12). Different filter materials may also be associated with different coefficients [1].  
 
Pharmacokinetic changes due to variability of CRRT 
The issue is further complicated by the fact that continuous renal replacement therapy is not a single 
modality applied in a uniform way. Instead considerable variation in effluent rate between patients and 
between Intensive Care Units is common, filter or dialyzer material may vary and replacement fluid may 
be infused pre or post filter. Furthermore it is frequently not continuous but is interrupted for technical 
reasons and to transport the patient out of the Intensive Care, e.g. for imaging or surgery. During these 
periods of downtime there is no CRRT clearance and therefore the actual (or delivered) CRRT clearance 
may be considerably lower than prescribed. 
Thus dosing of antibiotics should take into account changes in patient characteristics such as volume of 
distribution and changes in non-renal clearance, the killing characteristics of the antibiotic, the minimum 
inhibitory concentration of the target organism, the effluent rate and saturation or sieving coefficient as 
well as the fact that  these coefficients may change with acute phase changes in plasma protein 
concentrations. Given this, it is not surprising that non-individualized dosing results in a large proportion 
of patients being either under or overdosed [9-11] resulting in calls for more individualized dosing [9,12-
14]. In our previous review we proposed an individualized approach based on both pharmacokinetic and 
microbiological considerations. We recommended an initial dose based on the published volume of 
distribution and subsequent doses be based on an estimate of total clearance - total clearance being the 
sum of residual renal clearance, non-renal non-CRRT clearance and CRRT clearance. We proposed that 
CRRT clearance should be calculated using the equations given above and data obtained from critically ill 
patients. This approach, like all other dose adjustments for CRRT, has not been formally validated. 
Nevertheless, since our previous review other authors have advocated a similar approach [15-17] and 
recent data provide some supportive evidence. 
 
Prescription of initial loading dose and subsequent maintenance doses 
Our recommendation is to base the initial dose on the published volume of distribution of each specific 
antibiotic in critically ill patients and the target concentration of that antibiotic. As volume of 
distribution is either unchanged or increased in the critically ill, this will lead to patients receiving at 
least the standard dose of antibiotic. Dosing that does not take into account changes in volume of 
distribution will lead to low initial serum concentrations [18].  
Furthermore if our method of estimating CRRT clearance is correct then total clearance, half life and 
serum concentrations will be dependent, to some extent, on effluent rate. Yamamoto et al found that 
ratio of predicted clearance (based on an in vitro measurement of unbound fraction and effluent rate) 
to actual clearance ranged from 0.67 to 1.5[16]. Beumier et al found that serum concentrations of 
meropenem, ceftazidime, cefepime and piperacillin-tazobactam were correlated with effluent rate 
despite the fact that only the initial drug dose was fixed (subsequent doses were adjusted according to 
serum concentrations)[11]. Similarly, effluent rate has been shown to be associated with piperacillin 
clearance [7], doripenem clearance [19] and vancomycin serum concentration [20]. Jamal et al 
systematically reviewed the literature and demonstrated that CRRT clearance of meropenem, 
piperacillin-tazobactam and vancomycin is associated with the effluent rate[21]. However, this finding 
needs to be interpreted with some caution. In some cases CRRT clearance was derived from the 
equations given above and therefore CRRT clearance and effluent rate would have been mathematically 
coupled. In contrast, Roberts et al found that trough concentrations of meropenem, piperacillin-
tazobactam, vancomycin and ciprofloxacin were not associated with effluent rate[10]. However, the 
dose of drug given was at the discretion of the treating clinicians who may have taken the effluent rate 
into account. Udy et al also found there was no relationship between clearance and CRRT settings[22]. 
Pharmacokinetic data to calculate an appropriate initial dose and to estimate non-renal non-CRRT 
clearance and CRRT clearance were given in our previous review and on our website 
(http://www.aic.cuhk.edu.hk/web8/PK_data.htm). Relevant pharmacokinetic data published since 2009 
are summarized in table 12. As antibiotic clearance by healthy kidneys is usually higher than clearance 
by CRRT, subsequent (maintenance) doses of renally excreted antibiotics should generally be decreased. 
However, colistin may be an exception, as described below.  
 
Dosing of Colistin and Daptomycin 
When we last reviewed the literature there was minimal in vivo data to guide prescribing of either 
colistin or daptomycin and we will therefore concentrate on these two agents. Dosing of colistin poses a 
particular challenge as the optimal pharmacokinetic/pharmacodynamic relationship is yet to be defined 
and there are limited pharmacokinetic data to guide dosage. It is usually administered in the form of a 
prodrug, colistin methanesulfonate, a proportion of which is hydrolyzed to the active compound, 
colistin. In patients with normal renal function colistin methanesulfonate is eliminated mainly by 
glomerular filtration with additional clearance contributed by tubular secretion. Colistin is filtered in the 
glomerulus but is extensively reabsorbed in the tubules so little is eliminated by the kidney. The actual 
mechanism of elimination is still not yet fully understood [23]. Both colistin methanesulfonate and 
colistin are eliminated by CRRT. In the case of colistin methanesulfonate, clearance by CRRT will be less 
than by healthy kidneys while for colistin clearance will be greater than by healthy kidneys. The net 
effect on colistin serum concentration should depend on the effluent rate. At high effluent rates the rise 
in colistin methanesulfonate concentration should be small and the clearance of colistin should be high 
and as a result it may be necessary to increase the maintenance dose. Conversely with low effluent rates 
it may be necessary to decrease the maintenance dose. This, assumes, however that non-renal 
clearance is unchanged in renal failure. Unfortunately there are only limited pharmacokinetic data 
available and neither the effect of renal failure on non-renal clearance nor the effect of effluent rates on 
serum concentrations have been systematically studied. 
In patients receiving CRRT with effluent rates of 2.1 – 3.4L/h a reduced dose of colistin (2 million units 8 
hourly) produced sub-optimal serum concentrations, leading the authors to suggest that dose reduction 
is not required and higher than standard doses should be considered [24]. Similarly in patients receiving 
CRRT with an effluent rate of 1.9-2.3L/h, Markou et al demonstrated that doses ranging from 1 million 
units 8 hourly to 2 million units 18 hourly produced sub-optimal serum colistin concentrations[25]. 
Significant colistin elimination may occur as a result of adsorption to haemofilter and dialysis 
membranes. Karanen et al demonstrated extracorporeal clearance of 4.33 l/h which was in excess of the 
effluent rate (2.1-3.4 L/h)[24]. This cannot occur with haemodiafiltration alone, suggesting that 
adsorption occurred. Similarly in Markou’s study the clearance of colistin by haemodiafiltration was only 
0.67-0.81 L/hour but overall extracorporeal clearance was 1.83-1.93 L/hr[25]. Leporati et al reported 
large difference in pre and post-filter serum colistin concentration. Thus, significant adsorption appears 
to occur but the factors which determine the extent of colistin elimination by adsorption are unknown, 
complicating attempts to dose appropriately [26]. 
 In view of the uncertainty regarding colistin pharmacokinetics combined Together with the 
unknownuncertainty regarding the optimal  pharmacokinetic / pharmacodynamics target for colistin, 
theoretical dosing based on calculationtarget we do not recommend calculating a dose but suggest 
giving at least the recommended dose for patients with normal renal function (3 million units 8 hourly) 
for patients receiving  is not possible. We do not recommend areducing the dose of colistin of at leastto 
less than 3 million units 8 hourly (recommended i.e. dose for patients withas normal renal function) for 
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patient receiving CRRT with effluent rateswithin the range of 2.1– 3.4L/h. Other authors have suggested 
a more aggressive regime of a loading dose of 9 million units, followed by a maintenance dose of up to 
4.5 million units 8 hourly, without the risk of toxicity[27].  
 
Daptomycin exhibits concentration dependent kill characteristics. For susceptible Staphylococcus aureus 
with a  MIC of 0.5mg/L, a Cmax/ MIC ratio of 100–400, which corresponds to peak plasma concentration 
of 50–200 mg/l, is required[3]. The peak concentration achieved will depend predominantly on the dose 
and the volume of distribution. Peak concentrations achieved in critically ill patients receiving 3-8 mg/kg 
doses were sub-optimal in the majority of patients [3,4,28-31] presumably as a result of a volume of 
distribution that is approximately 2-3 times the volume of distribution in healthy volunteers [4,29]. The 
dosing interval will depend on the target trough concentration and the clearance of daptomycin. 
Elevated creatinine kinase, the major dose-related adverse effect, is more common when trough 
concentrations exceed 24.3 mg/l [32]. In healthy volunteers approximately 50% of a dose is eliminated 
by non-renal mechanisms and this does not appear to increase in critically ill patients receiving CRRT 
[28]. Daptomycin is removed by CRRT with a mean (SD) saturation coefficient of 0.13 (±0.05). Although 
CRRT clearance was found to be similar to renal clearance in healthy volunteers, the mean (SD) effluent 
rate of 36.7 (±13) ml/kg/h was high and clearance would be lower if the effluent rate was decreased[28].  
In view of its kill and toxicity characteristicsorder to optimise the pharmacokinetic / pharmacodynamic 
target, dDaptomycin dosing should be dosed usingbased on an extended interval dosing regime. Using 
According to the information and formulae above, and with the use of formula contained in the previous 
section and the method detailed in our previous publication [1][ref], athe minimum idealtheoretical 
dose and dosing interval required can be calculated. FDaptomycin for Staphylococcal aureus blood 
stream infection with MIC of 0.5 mg/L for a 70kg patient with anuria on CVVHD using a Polysulfone filter 
and with targeted total effluent of 35 ml/kg/hour, a  should be theoretically prescribed as loading dose 
of 800mg daptomycin with subsequent maintenance dosing interval of 34 hours shouldto achieve a 
Cmax/MIC of 100 and minimiseing the risk of adverse effects  . (Figure 1).  However  
 
iIt is important to appreciate  this calculated e theoretical dose calculated (11.5mg/kg) should also take 
into account the risk of toxicity and may needneed to be reduced to in order to comply with dose range 
approved by regulatory authorities. It is of interest to note that healthy individuals receiving 
dDaptomycin at doses up to 12mg/kg daily for 14 days didhave not developot been associated with 
adverse electrocardiographic or electrophysiological evidence of muscle or nerve toxicity[33].  
 
Use of Therapeutic Drug Monitoring (TDM) 
From the above it should be apparent that while it is possible to use published data and calculations of 
CRRT clearance to guide dosing, considerable uncertainty remains. For example volume of distribution 
of many antibiotics may vary considerably between patients, as may saturation and sieving coefficients 
(table 12). Furthermore changes in hepatic function, which are difficult to monitor clinically, may result 
in changes in non-renal non-CRRT clearance. As a result, use of therapeutic drug monitoring may be 
useful to adjust dosing regimes and are a routine part of care of patients receiving beta lactams and 
CRRT in some intensive care units [34]. Infusion rates are increased or decreased to achieve the desired 
target concentration depending on the result, which does not need to be available immediately. In 
practice, a change is required in 74% of cases, even in an ICU with expertise in antibiotic 
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pharmacokinetics and dosing [35]. In the future it may be possible to combine therapeutic drug 
monitoring with sophisticated pharmacokinetic models, which take into account the variability described 
above, to generate more appropriate individualized antibiotic dosing regimes [6]. 
Conclusions 
In summary the need to target pharmacokinetic end-points means that antibiotic dosing should take 
into account pharmacokinetic changes associated with critical illness, acute renal failure and CRRT. In 
general the volume of distribution of antibiotics is increased or unchanged in this group of patients. As a 
result initial doses should generally be increased or unchanged. Subsequent doses should be based on 
drug clearance, which will depend on residual renal clearance, non-renal non-CRRT clearance and 
delivered (as opposed to prescribed) CRRT clearance. As CRRT does not generally fully compensate for 
the reduction in renal clearance, maintenance doses should be decreased or unchanged. Once 
appropriate doses have been estimated further adjustment may be made based on the results of 
therapeutic drug monitoring. Future directions should include the conduct of large scale multi centre 
studies of patients receiving CRRT with creation of appropriate pharmacokinetic models which can be 
used to generate recommendations on dosing changes in response to the results of therapeutic drug 
monitoringling to account for the abovementioned variabilities. This should further be accompanied by 
development of therapeutic drug monitoring technique with a rapid turn-around time to allow prompt 
adjustment. 
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Figure legend 
Figure 1. Calculation of daptomycin dose Formatted: Font: Not Italic
Loading dose=Desired concentration x Vd (0.23 x 70 = 16 l) 
Desired concentration = 100 x MIC = 50 mg/l 
Loading dose = 50 x 16  800 mg 
Calculate CRRT clearance based on mode of CRRT, formulae in text  
& values from table 2 
ClCVVHD = Qd x Sd  
= 2450 x 0.14 = 343 ml/h  6 ml/min 
Pharmacokinetic 
target? 
Total clearance (Cltot) =residual renal clearance + calculated CRRT clearance + non renal non CRRT clearance 
= (0 + 6 +5) = 11 ml/min 
Calculate half-life 
= 0.693 x Vd / Cltot = 0.693 x 16000/11 
= 1008 min ~16.8 h  
Calculate time to reach target trough concentration 
Assuming target trough ≤24.3 mg/l to avoid adverse effect it will take 2 half lives  
for concentration to drop from 50 mg/l to target trough 
34 h 
Cmax:MIC ratio 
Repeat loading dose at 
calculated time (after 34 h) 
Time above 
threshold 
concentration 
Cmax:MIC &AUC24:MIC 
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